Subtopic Deep Dive

← Viral Infectious Diseases and Gene Expression in Insects

Baculovirus Expression Vector System
Research Guide

What is Baculovirus Expression Vector System?

The Baculovirus Expression Vector System (BEVS) uses modified baculoviruses to express recombinant proteins at high yields in insect cells such as Sf9 and High Five.

BEVS enables production of complex eukaryotic proteins with authentic post-translational modifications. Key reviews include Kost et al. (2005) with 989 citations on versatile baculovirus vectors for insect and mammalian cells. Over 100 papers document optimizations in glycosylation and bioreactor scale-up.

Curated Papers

Key Challenges

Why It Matters

BEVS supports structural biology and vaccine development by providing superior glycosylation compared to bacterial systems (Hollister, 1998; Hsu et al., 1997). Tripathi and Shrivastava (2019) highlight its role in large-scale therapeutic protein production for infectious diseases. Cid and Bolívar (2021) describe BEVS platforms for protein-based vaccines against global pathogens.

Key Research Challenges

Incomplete N-Glycosylation

Insect cells produce high-mannose N-glycans lacking β1,4-galactosyltransferase activity, limiting therapeutic protein efficacy. Hollister (1998) engineered Sf9 cells for stable mammalian galactosyltransferase expression to extend glycosylation pathways. Hsu et al. (1997) characterized differential N-glycan patterns in secreted IgG from Trichoplusia ni cells.

Cell Line Contamination Risks

Sf9 and High Five cell lines harbor covert viruses affecting product safety. Ma et al. (2014) identified a novel rhabdovirus in Spodoptera frugiperda lines using PCR and sequencing. Williams et al. (2017) detailed covert baculovirus infections in insects complicating bioreactor use.

Bioprocess Scale-Up Limits

Optimizing infection strategies and nutrient feeding for high-density cultures remains challenging. Hooker et al. (1999) compared IFN-γ transport and glycosylation constraints in insect versus CHO cells. Gallo-Ramírez et al. (2015) reviewed bioreactor designs for viral vaccine production.

Essential Papers

Baculovirus as versatile vectors for protein expression in insect and mammalian cells

Thomas A. Kost, J. Patrick Condreay, Donald L. Jarvis · 2005 · Nature Biotechnology · 989 citations

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Nagesh K. Tripathi, Ambuj Shrivastava · 2019 · Frontiers in Bioengineering and Biotechnology · 531 citations

Infectious diseases, along with cancers, are among the main causes of death among humans worldwide. The production of therapeutic proteins for treating diseases at large scale for millions of indiv...

Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing

Róisín O’Flaherty, Adam Bergin, Evangelia Flampouri et al. · 2020 · Biotechnology Advances · 234 citations

Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies

Raquel Cid, Jorge Bolı́var · 2021 · Biomolecules · 155 citations

To date, vaccination has become one of the most effective strategies to control and reduce infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were developed as live...

Covert Infection of Insects by Baculoviruses

Trevor Williams, Cristina Virto, Rosa Murillo et al. · 2017 · Frontiers in Microbiology · 132 citations

Baculoviruses (<i>Baculoviridae</i>) are occluded DNA viruses that are lethal pathogens of the larval stages of some lepidopterans, mosquitoes, and sawflies (phytophagous Hymenoptera). These viruse...

Stable expression of mammalian beta 1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells

Jason R. Hollister · 1998 · Glycobiology · 123 citations

An established lepidopteran insect cell line (Sf9) was cotransfected with expression plasmids encoding neomycin phosphotransferase and bovine beta 1,4-galactosyltransferase. Neomycin-resistant tran...

Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in Trichoplusia ni Cells

Tsu‐An Hsu, Noriko Takahashi, Yoshinori Tsukamoto et al. · 1997 · Journal of Biological Chemistry · 114 citations

Structures of the N-linked oligosaccharide attached to the heavy chain of a heterologous murine IgG2a produced from Trichoplusia ni (TN-5B1-4, High Five) insect cells were characterized. Coexpressi...

Reading Guide

Foundational Papers

Start with Kost et al. (2005, 989 citations) for BEVS overview in insect/mammalian cells; Hollister (1998) for glycosylation engineering; Hsu et al. (1997) for N-glycan analysis in Trichoplusia ni.

Recent Advances

Study Tripathi and Shrivastava (2019) for bioprocessing; Cid and Bolívar (2021) for vaccine platforms; Ma et al. (2014) for cell line virus risks.

Core Methods

Core techniques: Sf9/High Five cultures, polyhedrin promoter replacement, MOI optimization, stable galactosyltransferase lines (Hollister, 1998), mass spectrometry glycan profiling (Hooker et al., 1999).

How PapersFlow Helps You Research Baculovirus Expression Vector System

Discover & Search

Research Agent uses citationGraph on Kost et al. (2005, 989 citations) to map BEVS foundational works, then findSimilarPapers for glycosylation engineering papers like Hollister (1998). exaSearch queries 'Sf9 cell rhabdovirus contamination Ma 2014' to uncover hidden risks in cell lines.

Analyze & Verify

Analysis Agent applies readPaperContent to extract N-glycan structures from Hsu et al. (1997), then runPythonAnalysis with pandas to quantify glycan profiles across BEVS papers. verifyResponse (CoVe) and GRADE grading statistically verify claims on protein yields versus bacterial systems.

Synthesize & Write

Synthesis Agent detects gaps in scale-up strategies from Tripathi (2019) and Hooker (1999), flagging contradictions in glycosylation data. Writing Agent uses latexEditText for BEVS protocol revisions, latexSyncCitations to integrate 20+ references, and exportMermaid for infection multiplicity diagrams.

Use Cases

"Analyze N-glycan data from insect cell BEVS papers and plot distribution"

Research Agent → searchPapers 'BEVS glycosylation' → Analysis Agent → readPaperContent (Hsu 1997, Hollister 1998) → runPythonAnalysis (pandas/matplotlib glycan quantification plot) → researcher gets CSV-exported glycan statistics and visualization.

"Draft LaTeX review on BEVS vaccine production optimizations"

Synthesis Agent → gap detection (Cid 2021, Tripathi 2019) → Writing Agent → latexGenerateFigure (bioreactor schematic) → latexSyncCitations (Kost 2005 et al.) → latexCompile → researcher gets compiled PDF with synced references and diagrams.

"Find GitHub repos with BEVS protocol code from recent papers"

Research Agent → searchPapers 'BEVS bioreactor simulation' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (Gallo-Ramírez 2015 supplements) → researcher gets verified code for infection modeling and simulation scripts.

Automated Workflows

Deep Research workflow scans 50+ BEVS papers via citationGraph from Kost (2005), producing structured reports on glycosylation advances with GRADE scores. DeepScan applies 7-step CoVe analysis to Ma et al. (2014) contamination risks, checkpoint-verifying PCR methods. Theorizer generates hypotheses on engineering β1,4-galactosyltransferase for human-like glycans from Hollister (1998) data.

Try Doxa for Baculovirus Expression Vector System Research

Frequently Asked Questions

What defines the Baculovirus Expression Vector System?

BEVS uses recombinant baculoviruses with polyhedrin or p10 promoters to drive high-level protein expression in Sf9 or High Five insect cells (Kost et al., 2005).

What are core methods in BEVS?

Methods include baculovirus generation via Tn7 transposition (Bac-to-Bac system), multiplicity of infection optimization, and stable cell engineering for glycosylation (Hollister, 1998).

What are key BEVS papers?

Foundational: Kost et al. (2005, 989 citations) on vectors; Hollister (1998, 123 citations) on galactosyltransferase; Hsu et al. (1997, 114 citations) on IgG glycans.

What open problems exist in BEVS?

Challenges include full human glycosylation mimicry, covert virus detection in cell lines (Ma et al., 2014), and cost-effective bioreactor scale-up (Gallo-Ramírez et al., 2015).